Compass Therapeutics, Inc. (CMPX) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 13 Buy.
The consensus price target is $11.20 (low: $9.00, high: $15.00), representing an upside of 105.9% from the current price $5.44.
Analysts estimate Earnings Per Share (EPS) of $-0.35 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.36 vs est $-0.35 (missed -2.6%). 2025: actual $-0.42 vs est $-0.43 (beat +2.6%). Analyst accuracy: 97%.
CMPX Stock — 12-Month Price Forecast
$11.20
▲ +105.88% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Compass Therapeutics, Inc., the average price target is $11.20, with a high forecast of $15.00, and a low forecast of $9.00.
The average price target represents a +105.88% change from the last price of $5.44.
Highest Price Target
$15.00
Average Price Target
$11.20
Lowest Price Target
$9.00
CMPX Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Compass Therapeutics, Inc. in the past 3 months
EPS Estimates — CMPX
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.36
vs Est –$0.35
▼ 2.5% off
2025
Actual –$0.42
vs Est –$0.43
▲ 2.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CMPX
95%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 4.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
